Galectin Therapeutics Agrees With FDA On Belapectin For MASH Cirrhosis

Galectin Therapeutics reached an agreement with the FDA on the primary endpoint and regulatory pathway for belapectin in MASH cirrhosis patients. This alignment clarifies the Phase 3 protocol and supports the company's evaluation of strategic partnerships to support development.